Movers and SHAKERS
Reqorsa Receives Second Fast Track Designation
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Fast Track Designation With Immunotherapy. Genprex announced that the FDA has granted Fast Track Designation (FTD) for Reqorsa in combination with Keytruda (pembrolizumab) to treat non-small cell lung cancer (NSCLC). The company reiterated plans start testing the combination in the Phase 2 ACCLAIM-2 trial during 1Q22. We are raising our price target to $5 per share.
Reqorsa Is A Gene Therapy With Multiple Actions Reqorsa uses the proprietary Oncoprex technology to deliver TUSC2, a gene with suppressive actions on pathways for cancer growth and tumor survival that also magnifies the immune response against cancer. These actions as a suppressor gene and an immune stimulator have given it the name “immuogene therapy” ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.